Decreased plasma levels of soluble CD18 link leukocyte infiltration with disease activity in spondyloarthritis

Abstract

IntroductionSpondyloarthritis (SpA) comprises a group of diseases often associated with HLA-B27 and characterized by inflammation of the entheses and joints of the axial skeleton. The inflammatory process in SpA is presumably driven by innate immune cells but is still poorly understood. Thus, new tools for monitoring and treating inflammation are needed. The family of CD18 integrins is pivotal in guiding leukocytes to sites of inflammation, and CD18 hypomorphic mice develop a disease resembling SpA. Previously, we demonstrated that altered soluble CD18 (sCD18) complexes in the blood and synovial fluid of patients with arthritis have anti-inflammatory functions. Here, we study the mechanisms for these alterations and their association with SpA disease activity.MethodsPlasma levels of sCD18 in a study population with 84 patients with SpA and matched healthy controls were analyzed with a time-resolved immunoflourometric assay (TRIFMA). Binding of sCD18 to endothelial cells and fibroblast-like synoviocytes (FLSs) was studied with confocal microscopy. Shedding of CD18 from peripheral blood mononuclear cells (PBMCs) was studied with flow cytometry and TRIFMA.ResultsPlasma levels of sCD18 were decreased in patients with SpA compared with healthy volunteers (P <0.001), and the lowest levels were in the HLA-B27-positive subgroup (P <0.05). In a multiple regression model, the sCD18 levels exhibited an inverse correlation with the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) (P <0.05), the level of morning stiffness (P <0.05), the Bath Ankylosing Spondilitis Metrology Index (P <0.05), the physician global assessment score (P <0.01), and the sacroiliac magnetic resonance imaging activity score (P <0.05). The mechanisms for these changes could be simulated in vitro. First, sCD18 in plasma adhered to inflammation-induced intercellular adhesion molecule 1 (ICAM-1) on endothelial cells and FLS, indicating increased consumption. Second, CD18 shedding from SpA PBMCs correlated inversely with the BASDAI (P <0.05), suggesting insufficient generation. CD18 was shed primarily from intermediate CD14++ CD16+ monocytes, supporting the view that alterations in innate immunity can regulate the inflammatory processes in SpA.ConclusionsTaken together, the failure of patients with SpA to maintain adequate sCD18 levels may reflect insufficient CD18 shedding from monocytes to counterbalance the capture of sCD18 complexes to inflammation-induced ICAM-1. This could increase the availability of ICAM-1 molecules on the endothelium and in the synovium, facilitating leukocyte migration to the entheses and joints and aggregating disease activity.

Altered levels of soluble CD18 may associate immune mechanisms with outcome in sepsis

“…The concentration of sCD18 in serum is the result of a balance between shedding of CD18 from the surface of leucocytes and depletion through the binding of sCD18 to receptors such as ICAM‐1 expressed on cellular surfaces . The findings reported here suggest that high serum sCD18 concentrations could reflect an overweight of CARS (hypoinflammation), while low serum sCD18 concentrations reflect increased binding to up‐regulated ligands (hyperinflammation).…”

Tissue growth factor β stimulates fibroblast-like synovial cells to produce extra domain A fibronectin in osteoarthritis

“…Immunoflourescence of FLSs were done as previously described. [22] Sterile glass slides were placed in 24-well cell culture plates. FLSs were then seeded at a concentration of 5.0×10 4 cells/mL in DMEM and antibiotics supplemented with 5% FBS and incubated for 24 hours at 37°C.…”

Spondyloarthritis and the gut: A new look

“…Finally, several other options may arise via extrapolation of the therapeutic advances achieved in CIBD. For instance, integrin antagonists are being evaluated as potential treatments for CIBD [22,23] and adhesion molecules may be involved in SpA [24,25]. It might be worth assessing the impact of these new agents on the rheumatic manifestations.…”